Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

IBUPROFEN REQUIRED NDA FOR OTC MARKETING BECAUSE IT IS NEW, 200 MG DOSE, FDA TELLS CHATTEM IN MAY 18 REJECTION OF CITIZEN PETITION; POLICY DEFENDED

Executive Summary

The new 200 mg dose of ibuprofen required an NDA for approval for OTC marketing because "it has not been used to a material extent and for a material time," FDA declared in a May 18 response to the Chattem citizen petition to halt the NDA proceedings on the ingredient. "Experience with ibuprofen marketed as 300 mg, 400 mg and 600 mg strengths is pertinent to an evaluation of the drug's safety," FDA Associate Com. Joseph Hile told Chattem, "but such experience cannot support general recognition that the product, at a different strength and daily dose, can be used safely and effectively by the patient alone." The FDA response to Chattem's petition -- issued on the same day as agency approval of the ibuprofen OTC NDA -- sets at least one firm policy for Rx-to-OTC switches: a new dosage form of a switched product requires an NDA application and cannot be handled under the OTC Review monograph procedures. "Even if it could be established . . . that the 200 mg strength of ibuprofen had become generally recognized as safe and effective as a result of the investigations reported in the medical literature," Hile wrote, "the FDA has concluded that the drug should be regarded as a new drug within the meaning of 21 USC 321(p)(2), because it has not been used to a material extent and for a material time. A drug that has not been used to a material extent or for a material time is not appropriately included in the OTC monograph system." Technically, the ibuprofen approval is not viewed by FDA as an Rx-to-OTC switch. The agency observed that the 200 mg dose was not a previously marketed product. "Your petition," FDA told Chattem, "does not support your premise that the proposed approval of ibuprofen for OTC use involves a switch from Rx to OTC status. As noted . . . a 200 mg strength of ibuprofen has never been marketed in the U.S." Answering the Chattem request that the agency promulgate a policy for switching ingredients, FDA maintained that both the NDA procedures for moving an Rx product to OTC and the OTC Review procedures provide for public notice and comment on a switch. "FDA's established policy on switching Rx drugs to OTC status provides opportunity for public notice and comment, even where such switches are initiated through the filing of a supplemental NDA."

You may also be interested in...



Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data

Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011

FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance

FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials

Shire Hopes To Sow Future Deals With $50M Venture Fund

Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth

UsernamePublicRestriction

Register

PS063835

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel